05 December 2013 – Kirchner Group is pleased to announce that it acted as an advisor on structure and due diligence to the Alaska Permanent Fund in the Juno Therapeutics Inc. transaction.
Juno was founded with a $120M initial investment, which is among the largest fully committed Series A for a biotech startup in history.
Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner, Seattle Children’s Research Institute, joined together to launch Juno Therapeutics Inc. Juno will develop a broad pipeline of potentially revolutionary cancer immunotherapy products. Initial investors include leading technology venture capital firm ARCH Venture Partners and the Alaska Permanent Fund, through a partnership managed by Crestline Investors.
A copy of the press release announcing the formation of Juno Therapeutics Inc. can be read at their website.
For more information:
Patrick McNees
Managing Partner
Kirchner Group Health and Life Sciences
+1 205-789-7426
pmcnees@kirchnergroup.com